AngioDynamics (ANGO) Expected to Post Quarterly Earnings on Tuesday

AngioDynamics (NASDAQ:ANGO) is projected to post its Q4 2026 results before the market opens on Tuesday, July 14th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $80.2420 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2026 earning overview page for the latest details on the call scheduled for Tuesday, July 14, 2026 at 8:00 AM ET.

AngioDynamics Stock Down 0.8%

NASDAQ ANGO opened at $12.98 on Tuesday. AngioDynamics has a twelve month low of $8.36 and a twelve month high of $13.99. The business has a 50-day moving average price of $11.84 and a 200-day moving average price of $11.34. The firm has a market cap of $536.33 million, a price-to-earnings ratio of -17.31 and a beta of 0.34.

Hedge Funds Weigh In On AngioDynamics

A number of large investors have recently made changes to their positions in ANGO. Kotler Kevin bought a new stake in AngioDynamics in the fourth quarter worth about $21,997,000. UBS Group AG lifted its stake in shares of AngioDynamics by 83.6% during the 3rd quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock worth $12,315,000 after acquiring an additional 501,881 shares during the last quarter. Millennium Management LLC lifted its stake in shares of AngioDynamics by 28.1% during the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock worth $20,030,000 after acquiring an additional 393,682 shares during the last quarter. Nuveen LLC boosted its holdings in AngioDynamics by 40.5% during the 4th quarter. Nuveen LLC now owns 1,295,072 shares of the medical instruments supplier’s stock valued at $16,629,000 after acquiring an additional 373,110 shares during the period. Finally, State Street Corp grew its position in AngioDynamics by 33.0% in the 4th quarter. State Street Corp now owns 1,272,735 shares of the medical instruments supplier’s stock valued at $16,342,000 after acquiring an additional 315,844 shares during the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on ANGO. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Canaccord Genuity Group lowered their target price on AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Zacks Research lowered shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. Finally, Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.67.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.